XOMA Corp Articles
XOMA's perindopril and amlodipine FDC meets primary endpoint in Ph III blood pressure trial
23 November 2012
XOMA's allosteric insulin receptor-activating antibody first to improve glycemic control in vivo
12 March 2012
XOMA acquires US rights to perindopril franchise
18 January 2012
Executive changes at Onyx Pharma and XOMA
2 September 2011
ADA meeting hears news of XOMA’s new classes of insulin receptor-regulating Ab and Vivus’ Qnexa
27 June 2011
XOMA and Lab Servier in deal for multi-indication drug candidate worth a potential $505 million
5 January 2011
XOMA sells royalty rights on Cimzia for $4 million
20 August 2010
Showing 1-8 of 8 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
